22nd Century Group Inc (NASDAQ:XXII)
| 2.24 Delayed Data As of 3:59pm ET |  -0.03 / -1.32%Today’s Change | 1.42 Today|||52-Week Range 4.17 | -27.51% Year-to-Date |
Latest XXII News | Press Releases
| This Little-Known Tobacco Stock Is Getting a Huge Boost Jun 26 / MotleyFool.com - Paid Partner Content | If Biden Nixes Nicotine, 22nd Century Group Stock Could 10X Jun 25 / MotleyFool.com - Paid Partner Content |
Today’s Trading
| Previous close | 2.27 |
| Today’s open | 2.27 |
| Day’s range | 2.20 - 2.32 |
| Volume | 75,090 |
| Average volume (3 months) | 1,949,334 |
| Market cap | $348.8M |
Data as of 3:59pm ET, 07/06/2022
Growth & Valuation
| Earnings growth (last year) | -48.62% |
| Earnings growth (this year) | -1.19% |
| Earnings growth (next 5 years) | +30.00% |
| Revenue growth (last year) | +10.09% |
| P/E ratio | NM |
| Price/Sales | 15.60 |
| Price/Book | 5.23 |
Competitors
| ---- | ||
| BLUEbluebird bio Inc | -0.21 | -4.26% |
| MGTXMeiraGTx Holdings PL... | +0.32 | +4.09% |
| BTAIBioXcel Therapeutics... | +1.21 | +8.23% |
Data as of 4:00pm ET, 07/06/2022
Financials
| Next reporting date | August 10, 2022 |
| EPS forecast (this quarter) | -$0.06 |
| Annual revenue (last year) | $30.9M |
| Annual profit (last year) | -$32.6M |
| Net profit margin | -105.37% |
Profile
Sector Health Technology |
Industry Biotechnology |
No executives to display |
Corporate headquarters Buffalo, New York |
Forecasts
